Navigation Links
Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
Date:6/24/2008

Bringing 14 Years of Proven Clinical Trial Capability into the Frontage

Suite of Services

MALVERN, Pa., June 24 /PRNewswire/ -- Frontage Laboratories (http://www.frontagelab.com) (Malvern and Exton, PA USA and Shanghai, P.R. China), a leading high quality provider of bioanalytical, pre-clinical and drug development services to the pharmaceutical industry, announced today it has completed the acquisition of Advanced Biomedical Research, Inc. (ABR) (http://www.abr-pharma.com) (Princeton and Hackensack, NJ USA), an international, full service clinical CRO. Frontage made an initial 20 percent equity investment in ABR in 2007 and acquires the remaining 80 percent equity with the completion of this transaction. Frontage and ABR now offer unparalleled formulation development, bioanalytical and GMP testing services, Phase I-II study performance in a state-of-the-art 72-bed Clinical Research Center, and international Phase II-IV CRO services.

The combined resources of Frontage and ABR offer clients the following benefits:

-- Single source for clinical, bioanalytical and drug development services;
-- Integrated program management from discovery to commercialization;

-- Cost-effective, collaborative R&D services;

-- Proven management team;

-- Proactive client-centric focus.

"It is Frontage's goal to be a leading full service provider of quality driven, responsive, client-centric, collaborative R&D services to the pharmaceutical industry. The completion of the acquisition of ABR is a key part of fulfilling that goal," said Dr. Song Li, Chairman & CEO of Frontage and newly appointed Chairman of ABR. "Over the years, ABR has proven to be a most valuable partner and resource in extending Frontage's capabilities into the performance and management of clinical trials. With our R&D services expertise in the US and China, and ABR's turn-key clinical CRO services for conducting and managing Phase I-IV clinical trials, the addition of ABR to the Frontage family allows us to offer a full spectrum of clinical testing and R&D pharmaceutical services to our clients."

Dr. Michael S. Willett, ABR Founder & President commented, "I am delighted to remain an integral part of ABR and to become a key member of the Frontage management team. By combining Frontage's R&D services and rapidly expanding presence in the US and China with ABR's international clinical CRO capabilities and experience in North America and Europe, we are positioned as few others to provide scientifically driven, on-time, cost-effective solutions to our clients through the life cycle of a compound's development." Dr. Willett continued, "I've repeatedly been impressed with the resourcefulness of our people to work together to solve difficult challenges and to offer proactive solutions to our customers. The learning curve of ABR and Frontage people working together has long since been removed from the equation."

"We believe the addition of ABR to Frontage provides a solid foundation in clinical trials to build upon and will accelerate the company's continued expansion in China," added Mr. Brett Tucker, Partner, Baird Capital Partners Asia, an equity investor in Frontage. "Frontage and ABR's shared commitment to high quality is readily apparent and their collaborative approach to advancing drug candidates through pre-clinical and clinical development stages to commercialization brings value to customers."

About Frontage Laboratories, Inc.

Frontage Laboratories, Inc. is a rapidly expanding pharmaceutical R&D services company located in the greater Philadelphia, PA area and Shanghai, P.R. China. Frontage recognizes the importance of developing cost-effective and efficacious pharmaceutical treatments; as a result, we are focused on collaborating with our clients to discover and develop new cures and healthcare advances. We are called on by leading pharmaceutical companies to solve complex development issues and advance their pharmaceutical products through FDA approval. Each employee plays an important part in the success of the organization.

Frontage Laboratories collaborates with our clients in the following areas:

-- Bioanalytical services -- Bioanalytical method development, validation and sample analysis supporting preclinical pharmacokinetic, toxicokinetic, and clinical pharmacokinetic studies;

-- Pharmaceutical analysis -- method development, validation and GMP sample testing for drug substances and finished products;

-- Formulation development -- immediate and sustained release tablets and capsules, injectables and oral liquids (including suspensions and emulsions), creams and ointments -- product development, clinical supplies and commercialization services;

-- Custom organic synthesis and API development, GMP manufacture and commercialization;
-- Technology transfer of formulation and synthesis processes;

-- Preclinical and biomarker research;

-- Regulatory affairs and strategies;

-- Data management and regulatory applications;

-- Drug development and program management;

-- GMP / GLP consulting services.

About Advanced Biomedical Research, Inc.

ABR is a full-service, Phase I-IV global CRO dedicated to meeting the needs of pharmaceutical, biotechnology, and medical device companies. ABR offers an extensive range of clinical services including clinical study design, strategic and regulatory consulting, project management, monitoring, clinical data management, biostatistics, pharmacokinetic and pharmacodynamic analysis, quality assurance auditing, medical writing, pharmacovigilance and regulatory submissions.

ABR's clinical research professionals have a successful track record of executing and managing Phase II-IV multicenter trials in North America, Europe and Asia, and our accomplished team has been involved in more than 400 clinical trials in the past 14 years. ABR's dedicated staff employ the latest information technology and project management tools coupled with their extensive knowledge and experience to perform, manage, monitor and analyze clinical trials in a cost-efficient and rapid manner.

ABR has evaluated numerous branded and generic compounds in its state-of- the-art Phase I-II clinical research facilities in New Jersey and performs a wide range of clinical trials including first-in-human, dose escalation, bioavailability, bioequivalence, PK/PD, fed-fasted, drug-drug and drug-alcohol interactions, thorough QT (TQT) evaluations, and proof-of-concept studies. Beginning in early 2009, ABR will be among a select few to offer radiolabel studies.

Existing and new clients interested in learning more about the collaborative R&D services of ABR and Frontage may contact Ed Bailey, Director, Business Development at +1 609 818 1800 or e-mail: edward.bailey@abr-clinical.com.


'/>"/>
SOURCE Frontage Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Codexis Appoints Singapore Laboratories Managing Director
2. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
3. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
4. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
5. Stiefel Laboratories Appoints Two New Members to Board of Directors
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
7. ARUP Laboratories Releases ARUP Consult(R) 2.0
8. Forest Laboratories Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression
9. Carrington Laboratories Common Stock Now Trading on the OTC Bulletin Board: CARN.OB
10. Free White Paper Helps Biotech Laboratories Maintain a High Level of Infection Control
11. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 2017 China Cord Blood Corporation (NYSE: ... provider of cord blood collection, laboratory testing, hematopoietic stem ... its unaudited financial results for the third quarter and ... 31, 2016. Third Quarter of Fiscal 2017 ... of fiscal 2017 increased by 18.6% to RMB200.9 million ...
(Date:2/24/2017)... (NASDAQ: VWR), the leading global independent provider of product and ... financial results for the fourth quarter and full year ended ... 4Q16 record quarterly net sales of $1.13 billion, up 1.6% ... 4Q16 EMEA-APAC segment net sales increased 0.4%, ... sales increased 2.5%, or down 0.9% on an organic basis, ...
(Date:2/23/2017)... 2017 ... share data, unaudited)Three Months Ended December 31,Twelve Months Ended ... $           ... 89026%Aldurazyme Net Product Revenue 3539(10)%9498(4)%Kuvan ... Product Revenue  756025%297303(2)%Vimizim Net Product ...
(Date:2/23/2017)... JOSE, Calif. , Feb. 23, 2017 /PRNewswire/ ... exclusive license for two key immunotherapy technologies from ... first technology provides a method to monitor a ... such as PD-L1 and CTLA-4.  The second license ... if a patient is likely to have an ...
Breaking Biology Technology:
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:1/31/2017)... 31, 2017  Spero Therapeutics, LLC, a biopharmaceutical ... treatment of bacterial infections, today announced it has ... from Pro Bono Bio Ltd (PBB) to bolster ... resistant forms of Gram-negative bacteria.   The assets acquired ... a PBB group company. "The acquisition ...
(Date:1/25/2017)... , Jan. 25, 2017 The Elements of ... (IAM) lifecycle is comprised of a comprehensive set ... purpose of maintaining digital identities and providing a ... applications. There are significant number of programs opted ... to time by optimizing processes and changing policies. ...
Breaking Biology News(10 mins):